Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | OSBP | P22059 | 1/20 | 0.69 |
| ▸ | RORC | P51449 | 1/20 | 0.69 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 10/20 | 0.62 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7741660 | 0.94 | USP2 (0.70) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1243707 | 0.90 | USP2 (0.66) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10929495 | 0.89 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10930823 | 0.89 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10929500 | 0.89 | USP2 (0.65) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8605712 | 0.89 | CYP46A1 (0.64) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3977940 | 0.89 | CYP46A1 (0.64) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3508152 | 0.89 | CYP46A1 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL103515 | 0.89 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4961477 | 0.89 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125941-A1 | METHOD FOR THE DIAGNOSTIC DETERMINATION OF THE RISK CAUSED BY AN ALTERED OXIDATIVE BALANCE | H&D S.r.l. (IT) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015151023-A1 | METHOD FOR THE DIAGNOSTIC DETERMINATION OF THE RISK CAUSED BY AN ALTERED OXIDATIVE BALANCE | H&D S.R.L. (IT) | 2015-10-08 | — | — | WO | disclosed |
| US-20140205617-A1 | Compositions and Methods for Treatment of Neoplastic Disease | TERMAN DAVID S (US) | 2014-07-24 | — | — | US | disclosed |
| US-8524218-B2 | Compositions and methods for treatment of neoplastic disease | TERMAN DAVID S (US) | 2013-09-03 | — | — | US | disclosed |
| US-20090123444-A1 | delivering a therapeutic agent to a solid tumor characterized by hypoxia, acidosis and hypertonicity comprising loading the therapeutic agent into sickle red blood cells; tissue targeted therapy; drug delivery | TERMAN DAVID | 2009-05-14 | — | — | US | disclosed |
| US-20050112141-A1 | Compositions and methods for treatment of neoplastic disease | GRANDVIEW, LLC | 2005-05-26 | — | — | US | disclosed |